by dyadic | Aug 13, 2026 | Press Releases
JUPITER, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (NASDAQ: DYAI) (the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and...
by dyadic | Aug 12, 2026 | Press Releases
Dyadic to host earnings call on August 12 at 5:00 pm ETJUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a...
by dyadic | Aug 4, 2026 | Press Releases
New agreement builds on commercialization and development of precision-fermented dairy proteins and enzymes while reinforcing Dyadic’s diversified commercialization strategyJUPITER, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (Nasdaq:...
by dyadic | Aug 3, 2026 | Press Releases
JUPITER, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology...
by dyadic | Jul 28, 2026 | Press Releases
Delivery of the Bundibugyo viral antigens to Fondazione Biotecnopolo di Siena (“FBS”) and Scripps Research demonstrates C1’s potential to accelerate vaccine and monoclonal antibody development, expand platform adoption, and create future commercial...
by dyadic | Jul 24, 2026 | Press Releases
JUPITER, Fla., July 24, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life...
